Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06969755 · ClinicalTrials.gov registry record · Phase 4
Biomarkers to Enhance Early Schizophrenia Treatment
A Phase 4 study, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
NCT06969755: Recruiting Phase 4 study, sponsored by Northwell Health.
NCT06969755 is a Phase 4 study that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 180 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06969755, a Phase 4 study, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
Study Summary
This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.
Primary Outcome
To compare the 12-week response rate of CLZ versus FL-APs (both risperidone and aripiprazole) utilizing the BPRS
Interventions
- DRUG clozapine
- DRUG risperidone
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2030-07-30 |
| Phase | Phase 4 |
What NCT06969755 shows while recruiting
NCT06969755 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which clozapine is the first listed.
NCT06969755 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06969755 about?
NCT06969755 is a clinical study titled "Biomarkers to Enhance Early Schizophrenia Treatment". This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.
What is the current status of trial NCT06969755?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2025-09-30. Estimated completion is 2030-07-30.
What interventions are being tested in trial NCT06969755?
The interventions under investigation include: clozapine (DRUG), risperidone (DRUG), aripiprazole (DRUG).
Who is sponsoring clinical trial NCT06969755?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06969755's enrollment target sits among peer trials
180 466th of 2000 higher than 1,525 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI